{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:38:57Z","timestamp":1773286737293,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The phosphodiesterase-5 inhibitor sildenafil was postulated to reduce the risk for Alzheimer\u2019s Disease. Since preclinical data revealed beneficial effects in Huntington\u2019s Disease (HD), we now for the first time investigated effects of sildenafil in HD patients using the database ENROLL-HD. We demonstrate beneficial effects on motoric, functional and cognitive capacities in cross-sectional data. Those effects were not explained by underlying fundamental molecular genetic or demographic data. It remains unsolved, if effects are due to behavioral differences or due to direct dose-dependent neurobiological modulations.<\/jats:p>","DOI":"10.1007\/s00415-022-11196-7","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T13:05:41Z","timestamp":1653743141000},"page":"5144-5150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Resurrection of sildenafil: potential for Huntington\u2019s Disease, too?"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9950-7877","authenticated-orcid":false,"given":"Jannis","family":"Achenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Faissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Saft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"key":"11196_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-021-00138-z","author":"J Fang","year":"2021","unstructured":"Fang J, Zhang P, Zhou Y et al (2021) Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer\u2019s disease. Nat Aging. https:\/\/doi.org\/10.1038\/s43587-021-00138-z","journal-title":"Nat Aging"},{"key":"11196_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO (2007) Huntington\u2019s disease. Lancet 369:218\u2013228. https:\/\/doi.org\/10.1016\/S0140-6736(07)60111-1","journal-title":"Lancet"},{"key":"11196_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RAC Roos","year":"2010","unstructured":"Roos RAC (2010) Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis 5:40. https:\/\/doi.org\/10.1186\/1750-1172-5-40","journal-title":"Orphanet J Rare Dis"},{"key":"11196_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.785703","volume":"15","author":"H Komatsu","year":"2021","unstructured":"Komatsu H (2021) Innovative Therapeutic approaches for Huntington\u2019s disease: from nucleic acids to GPCR-targeting small molecules. Front Cell Neurosci 15:785703. https:\/\/doi.org\/10.3389\/fncel.2021.785703","journal-title":"Front Cell Neurosci"},{"key":"11196_CR5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/mds.27849","volume":"34","author":"EJ Wild","year":"2019","unstructured":"Wild EJ, Tabrizi SJ (2019) One decade ago, one decade ahead in Huntington\u2019s disease. Mov Disord 34:1434\u20131439. https:\/\/doi.org\/10.1002\/mds.27849","journal-title":"Mov Disord"},{"key":"11196_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.110822","volume":"134","author":"SM Nabavi","year":"2019","unstructured":"Nabavi SM, Talarek S, Listos J et al (2019) Phosphodiesterase inhibitors say NO to Alzheimer\u2019s disease. Food Chem Toxicol 134:110822. https:\/\/doi.org\/10.1016\/j.fct.2019.110822","journal-title":"Food Chem Toxicol"},{"key":"11196_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.brainresbull.2019.09.001","volume":"153","author":"L Liu","year":"2019","unstructured":"Liu L, Xu H, Ding S et al (2019) Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer\u2019s disease. Brain Res Bull 153:223\u2013231. https:\/\/doi.org\/10.1016\/j.brainresbull.2019.09.001","journal-title":"Brain Res Bull"},{"key":"11196_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/ADR-200191","volume":"4","author":"O Sanders","year":"2020","unstructured":"Sanders O, Rajagopal L (2020) Phosphodiesterase inhibitors for Alzheimer\u2019s disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale. J Alzheimers Dis Rep 4:185\u2013215. https:\/\/doi.org\/10.3233\/ADR-200191","journal-title":"J Alzheimers Dis Rep"},{"key":"11196_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0960327120960775","volume":"40","author":"MA Ibrahim","year":"2021","unstructured":"Ibrahim MA, Haleem M, AbdelWahab SA et al (2021) Sildenafil ameliorates Alzheimer disease via the modulation of vascular endothelial growth factor and vascular cell adhesion molecule-1 in rats. Hum Exp Toxicol 40:596\u2013607. https:\/\/doi.org\/10.1177\/0960327120960775","journal-title":"Hum Exp Toxicol"},{"key":"11196_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073664","volume":"8","author":"A Saavedra","year":"2013","unstructured":"Saavedra A, Giralt A, Arum\u00ed H et al (2013) Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington\u2019s disease. PLoS ONE 8:e73664. https:\/\/doi.org\/10.1371\/journal.pone.0073664","journal-title":"PLoS ONE"},{"key":"11196_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/978-3-319-58811-7_11","volume":"17","author":"FR Fusco","year":"2017","unstructured":"Fusco FR, Paldino E (2017) Role of Phosphodiesterases in Huntington\u2019s Disease. Adv Neurobiol 17:285\u2013304. https:\/\/doi.org\/10.1007\/978-3-319-58811-7_11","journal-title":"Adv Neurobiol"},{"key":"11196_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ejphar.2013.06.035","volume":"714","author":"T Thakur","year":"2013","unstructured":"Thakur T, Sharma S, Kumar K et al (2013) Neuroprotective role of PDE4 and PDE5 inhibitors in 3-nitropropionic acid induced behavioral and biochemical toxicities in rats. Eur J Pharmacol 714:515\u2013521. https:\/\/doi.org\/10.1016\/j.ejphar.2013.06.035","journal-title":"Eur J Pharmacol"},{"key":"11196_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.nbd.2010.01.013","volume":"38","author":"E Puerta","year":"2010","unstructured":"Puerta E, Hervias I, Barros-Mi\u00f1ones L et al (2010) Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis 38:237\u2013245. https:\/\/doi.org\/10.1016\/j.nbd.2010.01.013","journal-title":"Neurobiol Dis"},{"key":"11196_CR14","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/ene.13889","volume":"26","author":"JY Winder","year":"2019","unstructured":"Winder JY, Achterberg WP, Gardiner SL et al (2019) Longitudinal assessment of the Unified Huntington\u2019s Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington\u2019s disease. Eur J Neurol 26:780\u2013785. https:\/\/doi.org\/10.1111\/ene.13889","journal-title":"Eur J Neurol"},{"key":"11196_CR15","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1021\/acschemneuro.0c00244","volume":"11","author":"G Ribaudo","year":"2020","unstructured":"Ribaudo G, Ongaro A, Zagotto G et al (2020) Therapeutic potential of phosphodiesterase inhibitors against neurodegeneration: the perspective of the medicinal chemist. ACS Chem Neurosci 11:1726\u20131739. https:\/\/doi.org\/10.1021\/acschemneuro.0c00244","journal-title":"ACS Chem Neurosci"},{"key":"11196_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5603\/PJNNS.2020.0034","volume":"54","author":"PW Tipton","year":"2020","unstructured":"Tipton PW (2020) Sexual dysfunction in Huntington\u2019s disease: what do we really know? Neurol Neurochir Pol 54:291\u2013293. https:\/\/doi.org\/10.5603\/PJNNS.2020.0034","journal-title":"Neurol Neurochir Pol"},{"key":"11196_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/ene.13983","volume":"26","author":"M Picillo","year":"2019","unstructured":"Picillo M, Palladino R, Erro R et al (2019) The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson\u2019s disease. Eur J Neurol 26:1327\u20131333. https:\/\/doi.org\/10.1111\/ene.13983","journal-title":"Eur J Neurol"},{"key":"11196_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/brainsci11040413","volume":"11","author":"J Achenbach","year":"2021","unstructured":"Achenbach J, Saft C, Faissner S (2021) Longitudinal evaluation of the effect of tricyclic antidepressants and neuroleptics on the course of Huntington\u2019s disease\u2014data from a real world cohort. Brain Sci 11:413. https:\/\/doi.org\/10.3390\/brainsci11040413","journal-title":"Brain Sci"},{"key":"11196_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2021.05.012","volume":"88","author":"J Achenbach","year":"2021","unstructured":"Achenbach J, Saft C (2021) Data from ENROLL-HD: is the prevalence of juvenile and pediatric Huntington\u2019s disease overestimated? Parkinsonism Relat Disord 88:1\u20132. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.05.012","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11196-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T15:14:20Z","timestamp":1660058060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11196-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["11196"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11196-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"3 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict relevant to the content of this manuscript. JA declares no conflict of interest. SF received speaker\u2019s or board honoraria from Biogen, BMS, Celgene, Novartis and Roche and grant support from DMSG, Hertie-Stiftung, Ruhr-University Bochum, Lead Discovery GmbH and Novartis, unrelated to the content of this manuscript. CS reports personal fees \/ speaker\u2019s honoraria from Teva Pharma GmbH and Desitin GmbH, as well as non-financial support and other support from Registry-Euro-HD-Network, ENROLL-HD study (CHDI), MitoNet, PRIDE-HD (TEVA, Neurosearch), PROOF-HD (Prilenia), LEGATO (TEVA), and Amaryllis (Pfizer), AFQ056 (Novartis), ASO (IONIS Pharmaceuticals, Roche AG, WAVE) for the conducting of studies and grants from Biogen, the German Huntington foundation and CHDI all outside the submitted work and without relevance to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethic Committees of all sides that are part of the global multi-center longitudinal observational study ENROLL-HD. They are required to obtain and maintain local ethical approval (ClinicalTrials.govIdentifier: NCT01574053).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}